Monoclonal Antibodies and Immune Checkpoint Inhibitors in the treatment of Cancer

23k
Total downloads
71k
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 29 Oct 2024

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

Toshio Shimizu
John Powderly
Albiruni Abdul Razak
Patricia LoRusso
Kathy D. Miller
Steven Kao
Sarah Kongpachith
Catherine Tribouley
Michelle Graham
6 more
Anthony Tolcher

doi 10.3389/fonc.2024.1376551

1,098 views

REVIEW

Published on 30 Sep 2024

Prognostic biomarkers for immunotherapy in esophageal cancer

Xu Tong
Meiyuan Jin
Lulu Wang
Dongli Zhang
Yuping Yin
Qian Shen

doi 10.3389/fimmu.2024.1420399

817 views

ORIGINAL RESEARCH

Published on 15 Jul 2024

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells

Yunlong He
Depeng Yang
Xiaoyu Lin
Jinfeng Zhang
Rui Cheng
Liangyu Cao
Lijun Yang
Mengmeng Zhang
Xinyue Shi
6 more
Huan Nie

doi 10.3389/fimmu.2024.1412693

1,010 views

ORIGINAL RESEARCH

Published on 26 Jun 2024

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Cecilia Olsson Ladjevardi
Anthoula Koliadi
Viktoria Rydén
Ali Inan El-Naggar
Evangelos Digkas
Antonios Valachis
Gustav J. Ullenhag

doi 10.3389/fonc.2024.1399171

780 views
1 citation

CASE REPORT

Published on 24 May 2024

Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC

Liqianqi Chen
Suihao Zhang
Long Gong
Yucong Zhang

doi 10.3389/fonc.2024.1404045

615 views
1 citation

SYSTEMATIC REVIEW

Published on 17 May 2024

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Xin Shen
Jun Yang
Geng Qian
Mingyu Sheng
Yu Wang
Guohui Li
Jiaqing Yan

doi 10.3389/fonc.2024.1391724

708 views
3 citations

ORIGINAL RESEARCH

Published on 12 Apr 2024

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma

Wendy W. L. Lee
Jing Quan Lim
Tiffany P. L. Tang
Daryl Tan
Ser Mei Koh
Kia Joo Puan
Liang Wei Wang
Jackwee Lim
Kim Peng Tan
3 more
Olaf Rotzschke

doi 10.3389/fimmu.2024.1346178

2,137 views

SYSTEMATIC REVIEW

Published on 05 Apr 2024

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

Wenjing Zhang
Zhanpeng Liang
Yurong Zhao
Yanwei Li
Ting Chen
Wenxia Li
Yunqi Chen
Peiye Wu
Huatang Zhang
1 more
Luzhen Li

doi 10.3389/fimmu.2024.1359302

2,507 views
2 citations

CASE REPORT

Published on 29 Feb 2024

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report

Wang Deng
Juan Chen
Xin-Yu Deng

doi 10.3389/fimmu.2024.1333850

1,186 views
1 citation

REVIEW

Published on 12 Feb 2024

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Ting Yan
Lun Yu
Jiwen Zhang
Yun Chen
Yilan Fu
Jingyi Tang
Dehua Liao

doi 10.3389/fimmu.2024.1292122

2,527 views
3 citations

ORIGINAL RESEARCH

Published on 25 Jan 2024

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Ju-Li Lin
Mi Lin
Guang-Tan Lin
Qing Zhong
Jun Lu
Chao-Hui Zheng
Jian-Wei Xie
Jia-bin Wang
Chang-Ming Huang
Ping Li

doi 10.3389/fimmu.2024.1322152

716 views
3 citations

SYSTEMATIC REVIEW

Published on 24 Jan 2024

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review

Yun-zi Wang
Ji-sheng Wang
Jiang Du
Xue-li Tang
Jing-ping Xiao

doi 10.3389/fimmu.2024.1305810

1,452 views
2 citations

Share on

Frontiers in Oncology

Cancer Immunity and Immunotherapy

Participating Journals

Frontiers in Immunology
- Cancer Immunity and Immunotherapy
- 5.7 impact factor
- 9.8 citescore

Impact

71kTopic views
46kArticle views
23kArticle downloads

View impact

Submit your idea

Articles

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors

Prognostic biomarkers for immunotherapy in esophageal cancer

Neoadjuvant immunochemotherapy improves clinical outcomes of patients with esophageal cancer by mediating anti-tumor immunity of CD8+ T (Tc1) and CD16+ NK cells

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Case report: Regression after low-dose glucocorticoid therapy in a case of acute immune myocarditis induced by anti-PD-1 therapy for NSCLC

Treatment-related adverse events of immune checkpoint inhibitors in clinical trials: a systematic review and meta-analysis

Counterproductive effects of anti-CD38 and checkpoint inhibitor for the treatment of NK/T cell lymphoma

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report

Achilles’ Heel of currently approved immune checkpoint inhibitors: immune related adverse events

Oncological outcomes of sequential laparoscopic gastrectomy after treatment with camrelizumab combined with nab-paclitaxel plus S-1 for gastric cancer with serosal invasion

Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review

Frontiers in Oncology

Participating Journals

Impact